New PET Agent Provides Exceptional Same-Day Imaging for Clear Cell Renal Cell Carcinoma Patients

May 7, 2024

Reston, VA—A novel investigational PET imaging agent can rapidly and accurately visualize lesions in clear cell renal cell cancer (ccRCC) patients according to new research published in the May issue of The Journal of Nuclear Medicine. The results of the study suggest that the agent 68Ga-DPI-4452 (Debio 0328) is superior to standard CT imaging in the context of ccRCC. It also allows for significantly faster imaging and, in the future, could be utilized as part of a theranostic pair.

ccRCC accounts for 70-80 percent of renal cell carcinoma cases. Localized disease can be cured with surgery and ablative therapy regimens; however, one-third of patients present with or develop metastases, with poor prognosis. Despite major advances in treatment for renal cell carcinoma, the five-year relative survival rate for distant metastatic disease remains low.

“The carbonic anhydrase IX (CAIX) encoding gene is overexpressed in more than 90 percent of ccRCC cases and is restricted to gastrointestinal tissue, presenting both diagnostic and therapeutic opportunities” said Professor Michael Hofman MBBS, FRACP, FAANMS, nuclear medicine specialist at the Peter MacCallum Cancer Centre in Melbourne, Australia. “In this study, we aim to assess the safety, tolerability, and imaging characteristics of the CAIX-targeting imaging agent 68Ga-DPI-4452 (Debio 0328).”

This ongoing first-in-human GaLuCi study included three patients with histologically confirmed unresectable locally advanced or metastatic ccRCC who had received at least two lines of treatment in a metastatic setting. Patients received 68Ga-DPI-4452 (Debio 0328) and underwent whole-body PET/CT at 15 minutes, and one, two, and four hours after administration. Images from these three initial patients were analyzed, and pharmacokinetics and safety data were assessed.

68Ga-DPI-4452 (Debio 0328) offered outstanding imaging from the earliest time point with sustained tumor uptake up to four hours after administration. The agent was rapidly eliminated from the blood and urine, and no clinically significant toxicity was noted among the patients.

68Ga-DPI-4452 PET/CT revealed an exceptionally high tumor-to-background ratio, with background tissues nearly invisible with the exception of gastro-intestinal uptake. One-hour after administration was deemed the optimal time point for lesion assessment, which is substantially shorter than the three to seven days needed in previous PET imaging studies using antibody approaches,” said Hofman.

He continued, “Further work is now needed to assess whether this new imaging test could improve patient diagnosis, management, and outcomes. These findings are also encouraging for the evaluation of 177Lu-DPI-4452 (Debio 0228) as a treatment for ccRCC, which will be examined in the second arm of GaLuCi study.”

Figure 1. Whole-body maximum-intensity projections over time after [68Ga]Ga-DPI-4452 administration. (A) Representative PET images at 4 post-administration time points. (B) PET/CT image at 1 h to allow visualization of anatomic contour.

The authors of “First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma” include Michael S. Hofman, Ben Tran, and Mohammad B. Haskali, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia; Darren R. Feldman, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York; Anna Pokorska-Bocci, Solen Pichereau, Jonathan Wessen, Olena Vlasyuk, and Ivana Galetic, Debiopharm International SA, Lausanne, Switzerland; and Richard B. Sparks, CDE Dosimetry Services, Inc., Knoxville, Tennessee.

Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.


Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or

About JNM and the Society of Nuclear Medicine and Molecular Imaging

The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 16 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit